Gainers

• Impact BioMedical (AMEX:IBO) stock increased by 54.8% to $0.64 during Thursday's regular session. The company's market cap stands at $5.0 million.
• Tenaya Therapeutics (NASDAQ:TNYA) stock moved upwards by 32.43% to $0.77. The company's market cap stands at $125.8 million.
• Tango Therapeutics (NASDAQ:TNGX) shares rose 27.36% to $15.73. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q4 earnings came out today.
• OSR Holdings (NASDAQ:OSRH) shares increased by 21.9% to $0.5. The company's market cap stands at $10.5 million.
• uniQure (NASDAQ:QURE) shares rose 21.79% to $11.01. The market value of their outstanding shares is at $563.1 million. As per the press release, Q4 earnings came out 3 days ago.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock increased by 20.1% to $0.19.

Losers

• Medicus Pharma (NASDAQ:MDCX) shares fell 46.6% to $0.74 during Thursday's regular session. The company's market cap stands at $34.0 million.
• Helus Pharma (NASDAQ:HELP) shares decreased by 36.35% to $5.43. The company's market cap stands at $425.5 million.
• Sight Sciences (NASDAQ:SGHT) stock fell 25.7% to $4.02. The market value of their outstanding shares is at $286.0 million. As per the news, the Q4 earnings report came out yesterday.
• Can Fite Biopharma (AMEX:CANF) stock fell 19.61% to $4.84. The market value of their outstanding shares is at $7.8 million.
• Gossamer Bio (NASDAQ:GOSS) shares decreased by 15.85% to $0.49. The market value of their outstanding shares is at $134.2 million.
• Kala Bio (NASDAQ:KALA) shares decreased by 14.86% to $0.29. The market value of their outstanding shares is at $314.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.